BioCardia Announces FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
BioCardia, Inc. (NASDAQ: BCDA) has announced that the United States Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP Cell Therapy System for the treatment of heart failure. The CardiAMP Cell Therapy utilizes a patient’s own bone...